Financials in USD. Standardized financial statements.
A compact view of how Actinium Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $90,000 | $0 | $81,000 | $1.03M | $1.14M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | -100.0% | -92.1% | -10.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $811,000 | $0 | $0 | $524,000 | $447,000 | $420,089 | $50,721 | $55,938 | $77,523 |
| Gross Profit? | $90,000 | -$811,000 | $81,000 | $1.03M | $620,000 | -$447,000 | -$420,089 | -$50,721 | -$55,938 | -$77,523 |
| Gross Margin? | +100.0% | 0.0% | +100.0% | +100.0% | +54.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $36.34M | $41.31M | $52.00M | $35.13M | $25.58M | $21.95M | $21.65M | $23.83M | $26.91M | $26.85M |
| Operating Income? | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M |
| EBITDA? | -$35.43M | -$37.43M | -$51.13M | -$33.41M | -$24.25M | -$21.77M | -$21.48M | -$23.78M | -$26.86M | -$26.77M |
| Income Before Tax | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $173,359 | $0 | $5,007 |
| Net Income? | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| EPS? | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.37 | $-6.69 | $-11.96 | $-15.06 |
| Diluted EPS? | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 | $-1.83 | $-4.37 | $-6.69 | $-11.96 | $-15.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality